Skip to main content
. Author manuscript; available in PMC: 2023 Dec 28.
Published in final edited form as: Neurocrit Care. 2022 Nov 23;38(3):688–697. doi: 10.1007/s12028-022-01638-5

Figure 2.

Figure 2.

IL-10 production by microglia after inflammatory stimulation, without and with dexmedetomidine treatment. IL-10 expression increased after LPS stimulation (Naïve vs LPS mean difference = 156.8 ± 39.00 pg/mL, p = 0.0002). When using a t-test to analyze DEX treatment with certain inflammatory markers, DEX significantly decreased IL-10 expression in LPS-stimulated (mean difference = 74.93 ± 12.50, p = 0.0039) and Poly I:C-stimulated microglia (mean difference = 23.27 ± 6.405, p = 0.0221). There was no significant treatment effect from DEX observed in naïve microglia. Overall, DEX treatment significantly reduced IL-10 expression in cultures (2-way ANOVA, difference between predicted means = 39.33 ± 14.50, p<0.0001). (n = 3 for each treatment group; **** - p<0.0001)